human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024. Abstract LBA1000
[4]Xu B, Yan M, Ma F, et al. Abstract GS3-02: updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer. Cancer Res. 2022;82:GS3-02. [5]Hardy-Werbin M, ...
[1]Eroles P, Bosch A, Pérez-Fidalgo JA, et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. [2]Mandó P, Waisberg F, Pasquinelli R, et al. HER2-Directed Ther...
图3:TROPION-Breast01 研究 PFS 结果 在亚组分析中,无论既往使用 CDK4/6 抑制剂的时间是否超过 12 个月、既往接受过化疗线数(1 线或 2 线)、既往使用内分泌治疗时间是否超过 6 个月,Dato-DXd 治疗均有显著的 PFS 获益;在入组时不伴脑转移的亚组中,Dato-DXd 治疗也表现出了显著的 PFS 获益。相关的 ...
Krop I E, Kim S B, Martin A G, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18 (6):74...
[3]Yeung KT, Kalinsky K, Yau C, et al. Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab inCearly-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. 202...
REFERENCE: O’Brien B, Murthy R, Berry A, et al. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. J Clin Oncol. 2024;42(suppl 16): abstr 2018. doi:10.1200/JCO.2024.42.16_suppl.2018Recent...
[4]Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989-1995. ...
(DOR-IC) 的比率与先前的分析一致。参考来源：Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases 注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06...